Advanced Glycation End Products Induce Obesity and Hepatosteatosis in CD-1 Wild-Type Mice

BioMed Research International

Volumn 2016, Issue , 2016, Pages

  Sayej, Wael N ^a,b   Knight, Paul R ^c,d   Guo, Weidun Alan ^c   Mullan, Barbara ^c   Ohtake, Patricia J ^c   Davidson, Bruce A ^c,d   Khan, Abdur ^e   Baker, Robert D ^e   Baker, Susan S ^e  

^a Division of Pediatric Infectious Diseases   (United States)

^b UNIVERSITY OF CONNECTICUT SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY AT BUFFALO   (United States)

^d UNIVERSITY AT BUFFALO   (United States)

^e CHILDREN S HOSPITAL OF BUFFALO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT; INTERLEUKIN 6; LEPTIN; MYELOPEROXIDASE; TUMOR NECROSIS FACTOR ALPHA; PEROXIDASE; TUMOR NECROSIS FACTOR;

ADIPOSE TISSUE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CD-1 MOUSE; COMPARATIVE STUDY; CONTROLLED STUDY; CYTOKINE RESPONSE; ENZYME ACTIVITY; EPIDIDYMIS FAT; FAT CONTENT; INFLAMMATION; LIVER HISTOLOGY; MALE; MOUSE; NONALCOHOLIC FATTY LIVER; NONHUMAN; NUTRIENT CONTENT; OBESITY; PATHOGENESIS; WEIGHT GAIN; ANIMAL; BIOSYNTHESIS; FATTY LIVER; GENETICS; HUMAN; LIPID DIET; LIVER; METABOLISM; OXIDATION REDUCTION REACTION; PATHOLOGY; PATHOPHYSIOLOGY;

ADIPOSE TISSUE; ANIMALS; DIET, HIGH-FAT; FATTY LIVER; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; INFLAMMATION; INTERLEUKIN-6; LEPTIN; LIVER; MICE; NON-ALCOHOLIC FATTY LIVER DISEASE; OBESITY; OXIDATION-REDUCTION; PEROXIDASE; TUMOR NECROSIS FACTOR-ALPHA; WEIGHT GAIN;

EID: 84959422596     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2016/7867852     Document Type: Article

References (66)

1. Y. Falck-Ytter, Z. M. Younossi, G. Marchesini, and A. J. McCullough, "Clinical features and natural history of nonalcoholic steatosis syndromes," Seminars in Liver Disease, vol. 21, no. 1, pp. 17-26, 2001.
2. J. M. Clark, F. L. Brancati, and A. M. Diehl, "Nonalcoholic fatty liver disease," Gastroenterology, vol. 122, no. 6, pp. 1649-1657, 2002.
3. J. D. Browning and J. D. Horton, "Molecular mediators of hepatic steatosis and liver injury," The Journal of Clinical Investigation, vol. 114, no. 2, pp. 147-152, 2004.
4. I. R. Wanless and K. Shiota, "The pathogenesis of nonalcoholic steatohepatitis and other fatty liver diseases: a four-step model including the role of lipid release and hepatic venular obstruction in the progression to cirrhosis," Seminars in Liver Disease, vol. 24, no. 1, pp. 99-106, 2004.
5. C. P. Day andO. F. James, "Steatohepatitis: a tale of two "hits"?" Gastroenterology, vol. 114, no. 4, pp. 842-845, 1998.
6. C. P. Day, "Pathogenesis of steatohepatitis," Bailliere's Best Practice and Research in Clinical Gastroenterology, vol. 16, no. 5, pp. 663-678, 2002.
7. C. J. McClain, S. P. L. Mokshagundam, S. S. Barve et al., "Mechanisms of non-alcoholic steatohepatitis," Alcohol, vol. 34, no. 1, pp. 67-79, 2004.
8. G. Marchesini, M. Brizi, A. M. Morselli-Labate et al., "Association of nonalcoholic fatty liver disease with insulin resistance," American Journal ofMedicine, vol. 107, no. 5, pp. 450-455, 1999.
9. K. Nanda, "Non-alcoholic steatohepatitis in children," Pediatric Transplantation, vol. 8, no. 6, pp. 613-618, 2004.
10. S. Ten and N. Maclaren, "Insulin resistance syndrome in children," The Journal of Clinical Endocrinology & Metabolism, vol. 89, no. 6, pp. 2526-2539, 2004.
11. C. J. McClain, Z. Song, S. S. Barve, D. B. Hill, and I. Deaciuc, "Recent advances in alcoholic liver disease. IV. Dysregulated cytokine metabolism in alcoholic liver disease," The American Journal of Physiology-Gastrointestinal and Liver Physiology, vol. 287, no. 3, pp. G497-G502, 2004.
12. G. C. Farrell and C. Z. Larter, "Nonalcoholic fatty liver disease: from steatosis to cirrhosis," Hepatology, vol. 43, no. 2, supplement 1, pp. S99-S112, 2006.
13. M. H. Fishbein, C. Mogren, T. Gleason, and W. R. Stevens, "Relationship of hepatic steatosis to adipose tissue distribution in pediatric nonalcoholic fatty liver disease," Journal of Pediatric Gastroenterology and Nutrition, vol. 42, no. 1, pp. 83-88, 2006.
14. S. Horiuchi, "The liver is the main site for metabolism of circulating advanced glycation end products," Journal of Hepatology, vol. 36, no. 1, pp. 123-125, 2002.
15. D. Svistounov and B. Smedsrod, "Hepatic clearance of advanced glycation end products (AGEs)-myth or truth?" Journal of Hepatology, vol. 41, no. 6, pp. 1038-1040, 2004.
16. H. Hyogo, S.-I. Yamagishi, K. Iwamoto et al., "Elevated levels of serum advanced glycation end products in patients with non-alcoholic steatohepatitis," Journal of Gastroenterology and Hepatology, vol. 22, no. 7, pp. 1112-1119, 2007.
17. K. Iwamoto, K. Kanno, H. Hyogo et al., "Advanced glycation end products enhance the proliferation and activation of hepatic stellate cells," Journal of Gastroenterology, vol. 43,no. 4, pp. 298-304, 2008.
18. M. Takeuchi, A. Sakasai-Sakai, T. Takata et al., "Serum levels of toxic AGEs (TAGE) may be a promising novel biomarker in development and progression of NASH," Medical Hypotheses, vol. 84, no. 5, pp. 490-493, 2015.
19. C. Sharma, A. Kaur, S. S. Thind, B. Singh, and S. Raina, "Advanced glycation end-products (AGEs): an emerging concern for processed food industries," Journal of Food Science and Technology, vol. 52, no. 12, pp. 7561-7576, 2015.
20. C. Cerami, H. Founds, I. Nicholl et al., "Tobacco smoke is a source of toxic reactive glycation products," Proceedings of the National Academy of Sciences of the United States of America, vol. 94, no. 25, pp. 13915-13920, 1997.
21. S. Yamagishi, T. Matsui, and K. Nakamura, "Possible involvement of tobacco-derived advanced glycation end products (AGEs) in an increased risk for developing cancers and cardiovascular disease in former smokers," MedicalHypotheses, vol. 71, no. 2, pp. 259-261, 2008.
22. T. Kimura, J. Takamatsu, K. Ikeda, A. Kondo, T. Miyakawa, and S. Horiuchi, "Accumulation of advanced glycation end products of the Maillard reaction with age in human hippocampal neurons," Neuroscience Letters, vol. 208, no. 1, pp. 53-56, 1996.
23. J. W. Baynes, "The role of AGEs in aging: causation or correlation," Experimental Gerontology, vol. 36, no. 9, pp. 1527-1537, 2001.
24. J. W. Baynes, "The Maillard hypothesis on aging: time to focus on DNA," Annals of the New York Academy of Sciences, vol. 959, pp. 360-367, 2002.
25. T. Buetler and T. Henle, "The effects of AGEing on diet," The American Journal of Pathology, vol. 174, no. 1, pp. 351-353, 2009.
26. W. Cai, J. C. He, L. Zhu et al., "Oral glycotoxins determine the effects of calorie restriction on oxidant stress, age-related diseases, and lifespan," The American Journal of Pathology, vol. 173, no. 2, pp. 327-336, 2008.
27. C.-D. Agardh,U. Stenram,O. Torffvit, and E. Agardh, "Effects of inhibition of glycation and oxidative stress on the development of diabetic nephropathy in rats," Journal of Diabetes and Its Complications, vol. 16, no. 6, pp. 395-400, 2002.
28. B. O. Boehm, S. Schilling, S. Rosinger et al., "Elevated serum levels of N(epsilon)-carboxymethyl-lysine, an advanced glycation end product, are associated with proliferative diabetic retinopathy and macular oedema," Diabetologia, vol. 47, no. 8, pp. 1376-1379, 2004.
29. T. Koschinsky, C.-J. He, T. Mitsuhashi et al., "Orally absorbed reactive glycation products (glycotoxins): an environmental risk factor in diabetic nephropathy," Proceedings of the National Academy of Sciences of the United States of America, vol. 94, no. 12, pp. 6474-6479, 1997.
30. M. U. Ahmed, E. Brinkmann Frye, T. P. Degenhardt, S. R. Thorpe, and J. W. Baynes, "N-epsilon-(carboxyethyl)lysine, a product of the chemical modification of proteins by methylglyoxal, increases with age in human lens proteins," The Biochemical Journal, vol. 324, part 2, pp. 565-570, 1997.
31. M. Takahashi, H. Hoshino, K. Kushida, K. Kawana, and T. Inoue, "Direct quantification of pentosidine in urine and serum by HPLC with column switching," Clinical Chemistry, vol. 42, no. 9, pp. 1439-1444, 1996.
32. R. Ramasamy, S. F. Yan, and A. M. Schmidt, "Methylglyoxal comes of AGE," Cell, vol. 124, no. 2, pp. 258-260, 2006.
33. T. Niwa, T. Katsuzaki, S. Miyazaki et al., "Immunohistochemical detection of imidazolone, a novel advanced glycation end product, in kidneys and aortas of diabetic patients," The Journal of Clinical Investigation, vol. 99, no. 6, pp. 1272-1280, 1997.
34. P. J. Thornalley, S. Battah, N. Ahmed et al., "Quantitative screening of advanced glycation endproducts in cellular and extracellular proteins by tandem mass spectrometry," Biochemical Journal, vol. 375, no. 3, pp. 581-592, 2003.
35. N. Ahmed and P. J. Thornalley, "Quantitative screening of protein biomarkers of early glycation, advanced glycation, oxidation and nitrosation in cellular and extracellular proteins by tandem mass spectrometry multiple reaction monitoring," Biochemical Society Transactions, vol. 31, no. 6, pp. 1417-1422, 2003.
36. E. Yagmur, F. Tacke, C. Weiss et al., "Elevation of N-(carboxymethyl)lysine-modified advanced glycation end products in chronic liver disease is an indicator of liver cirrhosis," Clinical Biochemistry, vol. 39, no. 1, pp. 39-45, 2006.
37. R. Ramasamy, S. J. Vannucci, S. S. D. Yan, K. Herold, S. F. Yan, and A. M. Schmidt, "Advanced glycation end products and RAGE: a common thread in aging, diabetes, neurodegeneration, and inflammation," Glycobiology, vol. 15, no. 7, pp. 16R-28R, 2005.
38. R. Abe and S.-I. Yamagishi, "AGE-RAGE system and carcinogenesis," Current PharmaceuticalDesign, vol. 14,no. 10,pp. 940-945, 2008.
39. K. Hiwatashi, S. Ueno, K. Abeyama et al., "A novel function of the receptor for advanced glycation end-products (RAGE) in association with tumorigenesis and tumor differentiation of HCC," Annals of Surgical Oncology, vol. 15, no. 3, pp. 923-933, 2008.
40. H. Kuniyasu, Y. Chihara, and H. Kondo, "Differential effects between amphoterin and advanced glycation end products on colon cancer cells," International Journal of Cancer, vol. 104, no. 6, pp. 722-727, 2003.
41. B. Bartling, N. Demling, R.-E. Silber, and A. Simm, "Proliferative stimulus of lung fibroblasts on lung cancer cells is impaired by the receptor for advanced glycation end-products,"American Journal of Respiratory Cell and Molecular Biology, vol. 34, no. 1, pp. 83-91, 2006.
42. P. Tesa?rov'a, M. Kalousov'a, M. J'achymov'a, O. Mestek, L. Petruzelka, and T. Zima, "Receptor for advanced glycation end products (RAGE)-soluble form (sRAGE) and gene polymorphisms in patients with breast cancer," Cancer Investigation, vol. 25, no. 8, pp. 720-725, 2007.
43. M. P. Vitek,K. Bhattacharya, J. M. Glendening et al., "Advanced glycation end products contribute to amyloidosis in Alzheimer disease," Proceedings of the National Academy of Sciences of the United States of America, vol. 91, no. 11, pp. 4766-4770, 1994.
44. S. Y. Ko, H. A. Ko, K. H. Chu et al., "The possible mechanism of Advanced Glycation End Products (AGEs) for Alzheimer's disease," PLoS ONE, vol. 10, no. 11, Article ID e0143345, 2015.
45. H. Unoki, H. Bujo, S.-I. Yamagishi, M. Takeuchi, T. Imaizumi, and Y. Saito, "Advanced glycation end products attenuate cellular insulin sensitivity by increasing the generation of intracellular reactive oxygen species in adipocytes," Diabetes Research and Clinical Practice, vol. 76, no. 2, pp. 236-244, 2007.
46. M. Chen, T. M. Curtis, and A. W. Stitt, "Advanced glycation end products and diabetic retinopathy," Current Medicinal Chemistry, vol. 20, no. 26, pp. 3234-3240, 2013.
47. D. L. Vander Jagt, "Methylglyoxal, diabetes mellitus and diabetic complications," DrugMetabolismand Drug Interactions, vol. 23, no. 1-2, pp. 93-124, 2008.
48. J. Su, P. A. Lucchesi, R. A. Gonzalez-Villalobos et al., "Role of advanced glycation end products with oxidative stress in resistance artery dysfunction in type 2 diabetic mice," Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 28, no. 8, pp. 1432-1438, 2008.
49. K. ?Sebekov'a, V. Kup?cov'a, R. Schinzel, and A. Heidland, "Markedly elevated levels of plasma advanced glycation end products in patients with liver cirrhosis-amelioration by liver transplantation," Journal of Hepatology, vol. 36, no. 1, pp. 66-71, 2002.
50. N. Ahmed, P. J. Thornalley, R. L?uthen et al., "Processing of protein glycation, oxidation and nitrosation adducts in the liver and the effect of cirrhosis," Journal of Hepatology, vol. 41, no. 6, pp. 913-919, 2004.
51. H. Hyogo and S.-I. Yamagishi, "Advanced glycation end products (AGEs) and their involvement in liver disease," Current Pharmaceutical Design, vol. 14, no. 10, pp. 969-972, 2008.
52. K. E. Davis, C. Prasad, P. Vijayagopal, S. Juma, B. Adams-Huet, andV. Imrhan, "Contribution of dietary advanced glycation end products (AGE) to circulating AGE: role of dietary fat," British Journal of Nutrition, vol. 114, no. 11, pp. 1797-1806, 2015.
53. C. Leung, C. B. Herath, Z. Jia et al., "Dietary glycotoxins exacerbate progression of experimental fatty liver disease," Journal of Hepatology, vol. 60, no. 4, pp. 832-838, 2014.
54. G. S. Hotamisligil, N. S. Shargill, and B. M. Spiegelman, "Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance," Science, vol. 259, no. 5091, pp. 87-91, 1993.
55. B. M. Spiegelman and G. S. Hotamisligil, "Through thick and thin: wasting, obesity, and TNF," Cell, vol. 73, no. 4, pp. 625-627, 1993.
56. G. S. Hotamisligil, P. Arner, J. F. Caro, R. L. Atkinson, and B. M. Spiegelman, "Increased adipose tissue expression of tumor necrosis factor in human obesity and insulin resistance," The Journal of Clinical Investigation, vol. 95, no. 5, pp. 2409-2415, 1995.
57. L. M. Frago and J. A. Chowen, "Hypothalamic leptin and ghrelin signaling as targets for improvement in metabolic control," Current Pharmaceutical Design, vol. 21, no. 25, pp. 3596-3605, 2015.
58. K. W. Williams, M. M. Scott, and J. K. Elmquist, "From observation to experimentation: leptin action in the mediobasal hypothalamus,"The American Journal of Clinical Nutrition, vol. 89, no. 3, pp. 985S-990S, 2009.
59. E. Balland and M. A. Cowley, "New insights in leptin resistance mechanisms in mice," Frontiers in Neuroendocrinology, vol. 39, pp. 59-65, 2015.
60. M. Debnath, S. Agrawal, A. Agrawal, and G. P. Dubey, "Metaflammatory responses during obesity: pathomechanism and treatment," Obesity Research & Clinical Practice, 2015.
61. M. Bana's, M. Olszanecka-Glinianowicz, and B. Zahorska-Markiewicz, "The role of tumor necrosis factor and interleukin-6 in polycystic ovary syndrome," PolskiMerkuriusz Lekarski, vol. 21, no. 125, pp. 489-491, 2006.
62. S. Ceccarelli, N. Panera, M. Mina et al., "LPS-induced TNF factor mediates pro-inflammatory and pro-fibrogenic pattern in non-alcoholic fatty liver disease," Oncotarget, vol. 6, no. 39, pp. 41434-41452, 2015.
63. J. S. Yudkin, C. D. A. Stehouwer, J. J. Emeis, and S. W. Coppack, "C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue?" Arteriosclerosis,Thrombosis, and Vascular Biology, vol. 19, no. 4, pp. 972-978, 1999.
64. J. S. Yudkin, M. Kumari, S. E. Humphries, and V. Mohamed-Ali, "Inflammation, obesity, stress and coronary heart disease: is interleukin-6 the link?" Atherosclerosis, vol. 148, no. 2, pp. 209-214, 2000.
65. R. Anty, S. Bekri,N. Luciani et al., "The inflammatoryC-reactive protein is increased in both liver and adipose tissue in severely obese patients independently from metabolic syndrome, type 2 diabetes, andNASH,"TheAmerican Journal ofGastroenterology, vol. 101, no. 8, pp. 1824-1833, 2006.
66. X. Wang, A. Ge, M. Cheng et al., "Increased hypothalamic inflammation associated with the susceptibility to obesity in rats exposed to high-fat diet," Experimental Diabetes Research, vol. 2012, Article ID 847246, 8 pages, 2012.